This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Feb 17;386(7):e17.

doi: 10.1056/NEJMc2114590.

Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes

Dimitrios Patoulias¹, Christodoulos Papadopoulos¹, Michael Doumas¹

Affiliations

PMID: 35172065
DOI: 10.1056/NEJMc2114590

Comment

Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes

Dimitrios Patoulias et al. N Engl J Med. 2022.

. 2022 Feb 17;386(7):e17.

doi: 10.1056/NEJMc2114590.

Authors

Dimitrios Patoulias¹, Christodoulos Papadopoulos¹, Michael Doumas¹

Affiliation

¹ Aristotle University of Thessaloniki, Thessaloniki, Greece dipatoulias@gmail.com.

PMID: 35172065
DOI: 10.1056/NEJMc2114590

No abstract available

PubMed Disclaimer

Comment in

Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
Frías JP, Fernández Landó L, Brown K. Frías JP, et al. N Engl J Med. 2022 Feb 17;386(7):e17. doi: 10.1056/NEJMc2114590. N Engl J Med. 2022. PMID: 35172067 No abstract available.

Comment on

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Frías JP, et al. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. N Engl J Med. 2021. PMID: 34170647 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information